CFZ533
Biological
Novartis Pharmaceuticals Corporation
Total Payments
$1.1M
Transactions
32
Doctors
3
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $55,095 | 2 | 0 |
| 2019 | $93,169 | 2 | 0 |
| 2018 | $313,369 | 11 | 1 |
| 2017 | $614,336 | 17 | 3 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.1M | 23 | 98.8% |
| Consulting Fee | $12,550 | 9 | 1.2% |
Payments by Type
Research
$1.1M
23 transactions
General
$12,550
9 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| POC STUDY IN DE NOVO RENAL TRANSPLANTATION | Novartis Pharmaceuticals Corporation | $542,656 | 0 |
| A MULTI CENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PARALLEL GROUP STUDY TO ASSESS THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EFFICACY OF CFZ533 IN PATIENTS WITH PRIMARY SJOGRENS SYNDROME | Novartis Pharmaceuticals Corporation | $395,275 | 0 |
| A PARTIALLY-BLINDED, ACTIVE-CONTROLLED, MULTICENTER, RANDOMIZED STUDY EVALUATING EFFICACY, SAFETY, TOLERABILITY, PHARMACOKINETIC (PK) AND PHARMACODYNAMIC (PD) OF AN ANTI-CD40 MONOCLONAL ANTIBODY, CFZ533, IN DE NOVO AND MAINTENANCE KIDNEY TRANSPLANT RECIPI | Novartis Pharmaceuticals Corporation | $111,431 | 0 |
| AN OPEN LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 12 WEEK TREATMENT WITH CFZ533 IN PATIENTS WITH GRAVES DISEASE | Novartis Pharmaceuticals Corporation | $9,344 | 0 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $4,713 | 1 |
Top Doctors Receiving Payments for CFZ533
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Mineola, NY | $1.1M | 22 |
| , M.D | Surgery | Nashville, TN | $9,890 | 5 |
| , MBBS, PHD, MPH | Internal Medicine | Ann Arbor, MI | $4,713 | 1 |
| , M.D | Infectious Disease | Rochester, MN | $2,660 | 4 |
Ad
Manufacturing Companies
Product Information
- Type Biological
- Total Payments $1.1M
- Total Doctors 3
- Transactions 32
About CFZ533
CFZ533 is a biological associated with $1.1M in payments to 3 healthcare providers, recorded across 32 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2020. In 2020, $55,095 was paid across 2 transactions to 0 doctors.
The most common payment nature for CFZ533 is "Unspecified" ($1.1M, 98.8% of total).
CFZ533 is associated with 5 research studies, including "POC STUDY IN DE NOVO RENAL TRANSPLANTATION" ($542,656).